Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BigHat Biosciences, Merck Enter AI Research Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BigHat Biosciences, Merck Enter AI Research Collaboration

To optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, has entered a collaboration with Merck to apply the company’s technology to design candidates for up to three drug discovery programs.
 
BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins. 
 
The companies will collaborate to optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules. The teams have initiated work on the first program and will use the power of the complementary skills sets within each research team to generate high-quality lead antibodies. 
 
Mark DePristo, co-founder and CEO of BigHat, said, “We are thrilled to be collaborating with Merck’s world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.”
 
“This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities,” said Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories. “We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics